Genomics
Scientists uncover viral vectors that cross the blood-brain barrier
Using a "directed-evolution" strategy in mice and macaques, scientists at the Broad Institute of Massachusetts Institute of Technology and Harvard have identified adeno-associated viruses that cross the blood-brain barrier, advancing efforts to develop neurological disease gene therapies. Read More
Multiplexed 'CAR Pooling' accelerates evaluation of anticancer cell therapy receptors
Researchers have developed a new method for comparing massive numbers of CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer. Read More
Cell & Gene Meeting on the Mesa 2022 Recap
The Science and Medicine Group team was onsite at this year's Cell & Gene Meeting on the Mesa getting the who, what, and when on the product announcements, science sessions, and deals taking place this year. Find out what we learned in our recap. Read More
Gene therapy targets overactive brain cells in mice, potential neurological treatment
University College London researchers have developed a gene therapy for neurological and psychiatric diseases that reduces the excitability of overactive brain cells. Tested in mice, the scientists contend the treatment could potentially be used in human brain diseases caused by excessive activity of a small number of brain cells. Read More
Academic CDMOs, like commercial ones, play critical role in CGT sector
The cell and gene therapy (CGT) industry is growing and academic contract development and manufacturing organizations (CDMOs) -- like their larger commercial counterparts -- are playing a critical role in the ecosystem, according to Stuart Curbishley, PhD, head of business and process development at the University of Birmingham’s Advanced Therapies Facility. Read More
Induced pluripotent stem cell technology offers potential treatment for hair loss
Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells. Read More
Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia
Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Antion Biosciences takes allogeneic approach to therapies with microRNA technology
Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs. Read More
CDMO Lonza continues drive to support cell and gene therapy commercial customers
In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies. Read More
Cell and gene therapy sector is in midst of an ‘industrial revolution’: Miguel Forte
Science Advisory Board spoke with Dr. Miguel Forte, CEO of Bone Therapeutics and president-elect of the International Society for Cell & Gene Therapy, at last week’s 2022 Cell & Gene Meeting on the Mesa about the state of the cell and gene therapy sector. Read More
Conferences
Cell Bio 2022
December 3-7
District of Columbia United States
Glasgow International Health Festival
January 25-26, 2023
Glasgow
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter